• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Premier Biomedical, ATS form Premier Biomedical Pain Management Solutions

Premier Biomedical, ATS form Premier Biomedical Pain Management Solutions

September 20, 2016
CenterWatch Staff

Premier Biomedical has announced the signing of an agreement forming a joint venture company with Advanced Technologies Solutions (ATS), a San Diego, California enterprise. The joint venture company, Premier Biomedical Pain Management Solutions, will develop and market natural and cannabis-based generalized, neuropathic, and localized pain relief treatment products. Sales for the initial product, an extended-duration topical patch, are expected in early 2017, with a variety of follow-on opioid-free pain relief products launching soon thereafter. Sample pain management products are being manufactured and will be available in limited quantities beginning next month.

This move solidifies the on-going cooperation between the two companies, and Premier Biomedical's strategy to focus on two major treatment divisions: cancer/neuro-psychiatric diseases and pain management. ATS Owner Ronald T. LaBorde will be a member of the board of directors of Premier Biomedical Pain Management Solutions and will head up its product development and production efforts.

In a related item, Premier Biomedical also announced the appointment of LaBorde to the board of directors of Premier Biomedical, effective immediately.

Ronald T. LaBorde, owner of Advanced Technologies Solutions, stated, "The Joint Venture between ATS and Premier Biomedical brings together the technology of advanced cannabinoid delivery platforms with the business expertise of a professional business team with a proven professional board of scientific advisors. The mutual end game for both companies is to provide chronic pain suffers a dependable method of reducing or even ending the dependence on opioid pain medication and all of its myriad side effects for the individual and society. Premier Biomedical Pain Management Solutions does just that with a variety of product solutions for managing pain which we all suffer with day to day. We want to solve that problem with an affordable delivery system that works for extended periods of time."

William A. Hartman, president and CEO of Premier Biomedical, said, "The formation of Premier Biomedical Pain Management Solutions is a major step forward for Premier Biomedical and perfectly complements our existing R&D programs taking us beyond R&D into a near-term revenue generating position. There is a real synergy between the technologies and capabilities of ATS and Premier Biomedical that will provide a viable pain treatment alternative to opioid-based pain medications and their potential for addiction and death. It is anticipated that the revenue generated by our pain treatment products will partially fund on-going R&D, reducing the dilution associated with borrowing capital."

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing